hansoh glp 1 Merck pays $112M upfront for Hansoh's preclinical GLP-1 Hansoh Pharma licenses dual incretin

It could thus be assumed that in a state of high cardiovascular risk, the body tries to limit disease progression by increasing the secretion of the protective agent GLP-1

doi: 10.1007/s00125-009-1344-5

Who Should and Should Not Consider GLP-1 Therapy With Crohn's Disease Candidates for GLP-1 therapy with Crohn's disease typically have well-controlled or remission-stage disease, stable inflammatory markers, adequate nutritional status, and documented need for weight management

Often simply called GLP-1 drugs or GLPs, glucagon-like peptide-1 receptor agonists work by mimicking a hormone our bodies naturally make

Notably, IGF-1 promotes neurogenesis in the hippocampus, and reduced IGF-1 levels have been linked to depressive-like behaviors in animal models [97, 98]